Beyondspring (BYSI) Receives Media Sentiment Score of 0.11
Press coverage about Beyondspring (NASDAQ:BYSI) has been trending somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Beyondspring earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.5212585556775 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Beyondspring (BYSI) and Its Competitors Financial Review (americanbankingnews.com)
- Biotech Advances Potential ‘Billion-Dollar Drug’ with New Trial Launch in China (investorideas.com)
- BeyondSpring Inc. (BYSI) Forecasted to Post FY2017 Earnings of ($4.44) Per Share (americanbankingnews.com)
- BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017 (finance.yahoo.com)
A number of equities research analysts have recently issued reports on BYSI shares. Maxim Group reiterated a “buy” rating and set a $52.00 price target on shares of Beyondspring in a research report on Friday, October 27th. HC Wainwright set a $60.00 price target on shares of Beyondspring and gave the company a “buy” rating in a research report on Thursday, October 26th. Seaport Global Securities started coverage on shares of Beyondspring in a research report on Tuesday, December 5th. They set a “buy” rating and a $56.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Beyondspring from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Beyondspring currently has a consensus rating of “Buy” and a consensus target price of $54.50.
Shares of Beyondspring (BYSI) opened at $28.45 on Wednesday. Beyondspring has a 12-month low of $16.55 and a 12-month high of $48.49.
Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.01. research analysts forecast that Beyondspring will post -4.43 earnings per share for the current year.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.